Replies to post #423953 on NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

Totally logical implication.

[Doc logic]

exwannabe and JerryCampbell,

Not comparing overall trial results as those results mean nothing to this trial. What is usable is matched SOC/placebo data from historical trials as a base line since there has been no known meaningful improvement in patient outcomes from treatment. Your arguments against are being stomped on by FDA guidance changes whether you like it or not because, well, patients that have crossed over to a treatment that works and live longer because of it deserve to have other patients and doctors know this too. Salvage therapy repotentiation by DC therapy has been documented in prior studies from years ago. Regulators know this and are taking this into consideration while you, on the other hand, after all the discussion on the board over the years are better informed than letting on which begs the question about why you would deny what regulators are proposing in their guidance and have already approved in some cases. Justice is making a list, checking it twice, gonna find out who’s ... ; ). Best wishes.

[sentiment_stocks]

Actually, I don't think in the end we'll see a KM curve that compares the DCVax-L treatment arm to the control arm of "a" or "combination of" specific past trials. Instead, I think they'll assemble a much larger compilation of control patients from other comparable trials or historical groupings whose data is statistically familiar to the patients in the DCVax-L trial. So for all we know, if there are patients from the check mate methylated patients matches the data from the DC Vax trial, they may pull from that trial for the control comparison as well. But what they won't be doing is comparing the DCVax-L treatment arm that is comprised of some specific combination both methylated and unmethylated patients, and comparing it to the control arm of the checkmate methylated only trial.

So instead of comparing to a like number of comparable control patients (99), they'll probably assemble a much larger group of comparable control patients and compare the 232 DCVax-L treatment arm to them. And guess what? I bet the DCVax-L treatment arm still beats, even when comparing to this much larger number of comparable control patients.

But we shall see. I wonder if Fife has seen? If he did, then he placed another $15 million bet down on NWBO to get his money back, and then some.